Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6
2016 ◽
Vol 51
(7)
◽
pp. 741-747
◽
2017 ◽
Vol 66
(1)
◽
pp. S83-S84
◽
2017 ◽
Vol 66
(1)
◽
pp. S3-S4
◽
Keyword(s):
Keyword(s):
2016 ◽
Vol 19
(12)
◽
pp. 1144-1156
◽